title: Effects of consumption of pomegranate juice on carotid intima-media thickness in men and women at moderate risk for coronary heart disease.
abstract: This randomized, double-blind, parallel trial assessed the influence of pomegranate juice consumption on anterior and posterior carotid intima-media thickness (CIMT) progression rates in subjects at moderate risk for coronary heart disease. Subjects were men (45 to 74 years old) and women (55 to 74 years old) with > or =1 major coronary heart disease risk factor and baseline posterior wall CIMT 0.7 to 2.0 mm, without significant stenosis. Participants consumed 240 ml/day of pomegranate juice (n = 146) or a control beverage (n = 143) for up to 18 months. No significant difference in overall CIMT progression rate was observed between pomegranate juice and control treatments. In exploratory analyses, in subjects in the most adverse tertiles for baseline serum lipid peroxides, triglycerides (TGs), high-density lipoprotein (HDL) cholesterol, TGs/HDL cholesterol, total cholesterol/HDL cholesterol, and apolipoprotein-B100, those in the pomegranate juice group had significantly less anterior wall and/or composite CIMT progression versus control subjects. In conclusion, these results suggest that in subjects at moderate coronary heart disease risk, pomegranate juice consumption had no significant effect on overall CIMT progression rate but may have slowed CIMT progression in subjects with increased oxidative stress and disturbances in the TG-rich lipoprotein/HDL axis.
authors.affiliation: Radiant Research and University of Chicago, Chicago, IL, USA. michaeldavidson@radiantresearch.com
authors.forename: Michael H
authors.initials: MH
authors.lastname: Davidson
authors.forename: Kevin C
authors.initials: KC
authors.lastname: Maki
authors.forename: Mary R
authors.initials: MR
authors.lastname: Dicklin
authors.forename: Steven B
authors.initials: SB
authors.lastname: Feinstein
authors.forename: Marysue
authors.initials: M
authors.lastname: Witchger
authors.forename: Marjorie
authors.initials: M
authors.lastname: Bell
authors.forename: Darren K
authors.initials: DK
authors.lastname: McGuire
authors.forename: Jean-Claude
authors.initials: JC
authors.lastname: Provost
authors.forename: Harley
authors.initials: H
authors.lastname: Liker
authors.forename: Michael
authors.initials: M
authors.lastname: Aviram
mesh_terms: D000368:Aged; D000975:Antioxidants / Q000494:pharmacology / Q000627:therapeutic use; D001628:Beverages; D002339:Carotid Arteries; D016893:Carotid Stenosis / Q000188:drug therapy* / Q000473:pathology; D003327:Coronary Disease / Q000517:prevention & control; D018592:Cross-Over Studies; D019587:Dietary Supplements; D004311:Double-Blind Method; D005260:Female; D005419:Flavonoids / Q000494:pharmacology / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D015227:Lipid Peroxidation / Q000187:drug effects; D029561:Lythraceae; D008297:Male; D008875:Middle Aged; D010636:Phenols / Q000494:pharmacology / Q000627:therapeutic use; D008517:Phytotherapy / Q000379:methods*; D059808:Polyphenols; D012016:Reference Values; D012720:Severity of Illness Index; D016896:Treatment Outcome; D017539:Tunica Intima / Q000187:drug effects / Q000473:pathology*; D017540:Tunica Media / Q000187:drug effects / Q000473:pathology*
chemical_list: D000975:Antioxidants; D005419:Flavonoids; D010636:Phenols; D059808:Polyphenols